

Table S1: Univariate and multivariate analysis in sensitivity analysis (N = 153).

		Relapse-free survival				Overall survival			
		Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
		HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
Age	> 65 vs. ≤ 65	1.21 (0.72-2.03)	0.464	1.47 (0.81-2.64)	0.203	1.45 (0.74-2.86)	0.279	2.08 (0.95-4.55)	0.066
Gender	male vs. female	1.01 (0.69-1.48)	0.950	1.00 (0.64-1.55)	0.984	0.74 (0.45-1.22)	0.241	0.71 (0.40-1.27)	0.250
Primary tumour	rectal vs. colon	1.30 (0.89-1.91)	0.179	1.24 (0.79-1.96)	0.353	1.14 (0.69-1.88)	0.616	1.23 (0.68-2.24)	0.490
Tumor grade	G3 vs. G1-2	0.93 (0.75-1.15)	0.485	1.03 (0.81-1.31)	0.811	0.81 (0.59-1.11)	0.195	0.89 (0.63-1.25)	0.500
T-stage	T3-4 vs. T1-2	0.90 (0.46-1.79)	0.769	1.12 (0.53-2.36)	0.766	1.06 (0.43-2.65)	0.896	0.99 (0.34-2.84)	0.982
N-stage	N1-2 vs. N0	1.31 (0.90-1.90)	0.153	1.37 (0.90-2.10)	0.147	1.28 (0.78-2.10)	0.327	1.50 (0.82-2.73)	0.186
Pre-operative CEA	> 5ng/ml vs. ≤ 5ng/ml	1.24 (0.85-1.82)	0.272	0.99 (0.64-1.54)	0.973	1.87 (1.09-3.23)	0.024	1.93 (1.06-3.54)	0.033
Metastases presentation	metachronous vs. synchronous	1.09 (0.70-1.72)	0.701	1.01 (0.61-1.66)	0.98	1.10 (0.61-1.96)	0.759	0.75 (0.38-1.49)	0.408
Number of metastases	≥ 3 vs. < 3	1.41 (0.97-2.05)	0.072	1.30 (0.83-2.01)	0.251	1.40 (0.85-2.33)	0.190	1.39 (0.75-2.57)	0.290
Size of the max metastases (cm)	> 3 vs. ≤ 3	1.20 (0.83-1.73)	0.342	1.16 (0.75-1.80)	0.498	1.24 (0.76-2.03)	0.386	0.91 (0.49-1.68)	0.755
Resection status	R1-2 vs. R0	2.86 (1.88-4.36)	< 0.001	2.20 (1.36-3.55)	0.001	2.94 (1.78-4.86)	< 0.001	2.36 (1.29-4.33)	0.006
Duration of preoperative CT	long vs. short	1.08 (0.75-1.56)	0.683	1.06 (0.69-1.63)	0.798	0.96 (0.59-1.58)	0.884	0.78 (0.43-1.42)	0.420
Chemotherapy backbone	CT with Bev vs. CT only	1.09 (0.64-1.87)	0.755	1.38 (0.76-2.50)	0.287	1.03 (0.50-2.12)	0.932	1.38 (0.62-3.07)	0.435
	CT with Cet vs. CT only	1.41 (0.85-2.33)	0.180	1.11 (0.61-2.00)	0.733	1.34 (0.71-2.55)	0.370	1.63 (0.78-3.38)	0.193
Response Evaluation	SD vs. PR	0.89 (0.61-1.29)	0.534	.80 (0.50-1.25)	0.323	1.23 (0.73-2.07)	0.430	1.52 (0.80-2.86)	0.199
TRG	TRG4-5 vs. TRG1-3	1.67 (1.15-2.42)	0.007	1.56 (1.01-2.41)	0.047	1.71 (1.05-2.79)	0.032	1.49 (0.83-2.66)	0.178
Postoperative chemotherapy	yes vs. no	0.64 (0.44-0.94)	0.023	0.54 (0.35-0.83)	0.005	0.52 (0.32-0.85)	0.010	0.48 (0.27-0.85)	0.012

Ten patients with rapidly progressing disease were excluded in this sensitivity analysis (N = 153). CEA = cantigen antigen. CT = chemotherapy. Bev = bevacizumab. Cet = cetuximab. CRS = clinical risk score. PR = partial response. SD = stable disease. TRG = tumor regression grade. &Six of 153 patients were unevaluable for radiological response.

Figure S1: Survival benefit of adjuvant chemotherapy post-metastasectomy based on risk stratification.




Figure S1: A-B. Survival curves according to treatment post-metastectomy in metachronous and synchronous metastases subgroups, respectively. C-D. Survival curves according to treatment post-metastectomy in differentiated grade 1-2 and grade 3 subgroups, respectively. E-F. Survival curves according to treatment post-metastectomy in metastases < 3 and ≥ 3 per patient subgroups, respectively. G-H. Survival curves according to treatment post-metastectomy in size of the max metastasis ≤ 3 and > 3 cm subgroups, respectively. I-J. Survival curves according to treatment post-metastectomy in short-duration and long-duration of pre-operative chemotherapy subgroups, respectively. K-L. Survival curves according to treatment post-metastectomy in PR and SD subgroups, respectively. M-N. Survival curves according to treatment post-metastectomy in TRG 1-3 and TRG 4-5 subgroups, respectively.